GW Pharmaceuticals plc today announces the launch in Denmark of Sativex® oromucosal spray as a treatment for the relief of spasticity in Multiple Sclerosis (MS).
Regulatory approval for Sativex® was granted in June 2011 by the health authorities in Denmark.
Sativex® was developed by UK-based GW Pharmaceuticals plc in specific response to the MS population's unmet need for a prescription cannabis-based medicine. Manufactured under Home Office licence at an undisclosed location in the UK it is marketed in Europe (except the UK) by Almirall.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1814